Recombinant AMACR / p504S Antibody (Prostate Cancer Marker), Clone: [rAMACR/6369], Mouse, Monoclonal

Catalog Number: NSJ-V9306-20UG
Article Name: Recombinant AMACR / p504S Antibody (Prostate Cancer Marker), Clone: [rAMACR/6369], Mouse, Monoclonal
Biozol Catalog Number: NSJ-V9306-20UG
Supplier Catalog Number: V9306-20UG
Alternative Catalog Number: NSJ-V9306-20UG
Manufacturer: NSJ Bioreagents
Host: Mouse
Category: Antikörper
Application: IHC-P, WB
Species Reactivity: Human
Immunogen: Recombinant full-length human AMACR protein was used as the immunogen for the recombinant AMACR antibody.
This antibody recognizes a protein of 42kDa, which is identified as AMACR, also known as p504S. It is an enzyme that is involved in bile acid biosynthesis and -oxidation of branched-chain fatty acids. AMACR is essential in lipid metabolism. It is expressed in cells of premalignant high-grade prostatic intraepithelial neoplasia (HGPIN) and prostate adenocarcinoma. The majority of the carcinoma cells show a distinct granular cytoplasmic staining reaction. AMACR is present at low or undetectable levels in glandular epithelial cells of normal prostate and benign prostatic hyperplasia. A spotty granular cytoplasmic staining is seen in a few cells of the benign glands. AMACR is expressed in normal liver (hepatocytes), kidney (tubular epithelial cells) and gall bladder (epithelial cells). Expression has also been found in lung (bronchial epithelial cells) and colon (colonic surface epithelium). AMACR expression can also be found in hepatocellular carcinoma and kidney carcinoma. Past studies have also shown that AMACR is expressed in various colon carcinomas (well, moderately and poorly differentiated) and over expressed in prostate carcinoma.
Clonality: Monoclonal
Clone Designation: [rAMACR/6369]
UniProt: Q9UHK6
Purity: Protein A/G affinity
Form: 0.2 mg/ml in 1X PBS with 0.1 mg/ml BSA (US sourced), 0.05% sodium azide
Antibody Type: Primary Antibody
Application Dilute: Western blot: 1-2ug/ml,Immunohistochemistry (FFPE): 1-2ug/ml
Application Notes: Optimal dilution of the recombinant AMACR antibody should be determined by the researcher.